NBE Therapeutics is developing _next-generationÓ antibody drug conjugates with enhanced potency, using its in-house developed proprietary technologies, against oncologic indications.
NBE Therapeutics AG
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
NBE-Therapeutics has developed a new and unique enzymatic antibody-payload conjugation platform SMAC-TechnologyTM to attach toxic small molecule drugs specifically and with a controlled ratio to antibodies. Due to the enzymatic reaction, the conjugation conditions are mild and keep the structure of the antibody fully intact. In addition two this new conjugation technology the company has proprietary antibody discovery and engineering platform Transpo-mAb technologyTM.
In Jan 2016, NBE Therapeutics and SOTIO a.s., collaborate on the discovery of novel cancer targeting ADC products based on NBEs proprietary antibody discovery and conjugation platforms. Under the terms, SOTIO invested CHF10Mn in equity in NBE and will have global responsibility for clinical development, registration and commercialization of the ADC products. Further, NBE will be eligible for an option exercise fee, milestone payments and royalties based on global net sales of the products. In addition, NBE to be reimbursed for its R&D expenses incurred in connection with the development of the products.
In Jun 2018, NBE-Therapeutics raised CHF 20 Mn extension of the Series B round, led by PPF Capital Partners Fund (PPF) with the participation of the Boehringer Ingelheim Venture Fund (BIVF) and private investors. Together with an earlier CHF 20 Mn series B financing, the total series B financing round of NBE-Therapeutics has reached to CHF 40 Mn. Novo Holdings becomes a major shareholder of NBE Therapeutics, alongside BIVF and PPF.
In Feb 2015, NBE-Therapeutics closes CHF 3.0 Mn Series A financing round led by Boehringer Ingelheim Venture Fund as lead investor to finance the development of a portfolio of first Antibody Drug Conjugate (ADC) development candidates against cancer. Till 2015, it raised CHF 5.5 Mn funds from its investors and CHF 4.0 Mn in funding from research grants for various academic collaborations.